Building on a Long Legacy of Medical Breakthroughs
At Tanabe Pharma America, we take on seemingly insurmountable obstacles – knowing it has the power to make a real difference in the lives of people struggling with debilitating diseases. It’s our responsibility and our honor.
OUR HISTORY
Our company has altered the course of history with the mantra that scientific breakthroughs can transform lives.
For more than 300 years, our parent company, Tanabe Pharma Corporation (previously Mitsubishi Tanabe Pharma Corporation) in Japan, has proudly pursued medical advances; we’ve discovered and produced several first in class medicines for serious diseases, including multiple sclerosis (MS) and diabetes mellitus (DM).
While our global successes represent a strong part of our identity, we continue to build on this legacy by seeking new therapies for the pressing needs of patients in the U.S. We pledge to uphold our legacy and wayfaring spirit – always seeking out solutions to their most pressing needs.
Company Snapshot
+300
Years of innovation
Headquartered in Jersey City, NJ
Not many companies have a legacy as long as ours. For over 300 years, we have maintained the highest ethical standards and have placed top priority on fairness and integrity, all while contributing to the healthier lives of people around the world through the creation of pharmaceuticals.
By taking on seemingly insurmountable obstacles, we give ourselves the opportunity to achieve scientific breakthroughs and make a real difference in the lives of people struggling with debilitating diseases.
OUR PEOPLE
Who We Are
Our people are tenacious and thrive on solving complex problems in science and medicine. This drive and personal commitment is at the core of our strength as an organization.
Meet Our PresidentWhen you join TPA, you’ll join a team dedicated to making a real difference in people’s lives.
Registration of Clinical Trial Information and Disclosure of Results
a. Registration of our clinical trial information, and disclosure of results, to clinical trial registries
TPA will register and disclose information on publicly accessible clinical trial registries such as ClinicalTrials.gov regarding clinical trials that are being conducted or have been conducted.
b. Disclosure of clinical trial summary results
TPA will disclose the results from clinical trials in patients that form part of the submission package for products approved in the United States. Results will not be disclosed if TPA decides that disclosure may lead to identification of clinical trial participants. Results may not be disclosed under any of the following conditions:
- A third party, such as a company involved in joint development, has not agreed to disclosure.
- Disclosure may interfere with publication in medical journals.
- Disclosure may interfere with the protection of intellectual property rights.